Seres Therapeutics, Inc., a clinical-stage company, focuses on developing biotherapeutics for serious diseases. The company develops SER-155, an investigational oral live biotherapeutic to decolonize GI pathogens, enhance GI epithelial barr...
Q2 2026
Aug 5, 2026
Q1 2026
May 5, 2026
FY 2025
Mar 12, 2026
Q4 2025
Q3 2025
Nov 5, 2025